* Actavis would take Valeant outside its area of expertise
* Shares of both companies on a tear this year
* Generic drug profits to grow
By Rod Nickel and Jessica Toonkel
WINNIPEG/NEW YORK, April 30 After five years and
some 60 deals that have turned Valeant Pharmaceuticals
International Inc into a stock market darling with a
market capitalization of $22 billion, Chief Executive Michael
Pearson still has some surprises up his sleeve.
One was the Canadian drugmaker's pursuit of U.S.-based
generic pharmaceutical company Actavis Inc, a prize
worth more than $13 billion that would be both Valeant's biggest
deal by far and a move into less familiar territory.
The deal stalled after the companies failed to agree on
terms, people familiar with the situation said. An Actavis
spokesman declined to comment and Valeant did not respond to
inquiries. It was not clear if the deal could be revived.